Endometrial Carcinoma clinical trials

Explore recruiting endometrial carcinoma clinical trials.

Recruiting endometrial carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Endometrial Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Netherlands, Greece, Denmark, Poland, Spain, Italy +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Ireland, Austria, Italy, Spain, Belgium, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

Italy, Spain, Denmark, Finland, Germany, Ireland +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study of Pembrolizumab combined with Ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2 Open-label, multicenter study to evaluate efficacy and safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

Spain, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Comparative Bioavailability of Lenvatinib 10 mg Capsules: A Two-Part, Single-Dose, Open-Label, Randomized, Six-Sequence, Three-Treatment, Three-Period, Crossover Pilot Study in Healthy Subjects Under Fasting and Fed Conditions.

Portugal

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Endometrial Carcinoma trials by city

Endometrial Carcinoma in Toronto Endometrial Carcinoma in Vancouver Endometrial Carcinoma in Montreal Endometrial Carcinoma in Calgary Endometrial Carcinoma in Edmonton Endometrial Carcinoma in Ottawa Endometrial Carcinoma in Winnipeg Endometrial Carcinoma in Quebec City Endometrial Carcinoma in Hamilton Endometrial Carcinoma in Kitchener Endometrial Carcinoma in London Endometrial Carcinoma in Halifax Endometrial Carcinoma in New York Endometrial Carcinoma in Los Angeles Endometrial Carcinoma in Chicago Endometrial Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease